In rodents, FXR engagement was shown to inhibit NAFLD-related liver pathologies, as well as protect from insulin and glucose intolerance (Cipriani et al., 2010; Verbeke et al., 2016). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.